Bessemer Group’s Maze Therapeutics MAZE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.5M Buy
496,253
+14,463
+3% +$401K 0.02% 347
2026
Q2
$14.4M Hold
481,790
– – 0.02% 346
2026
Q1
$14.4M Hold
481,790
– – 0.02% 312
2025
Q4
$20M Hold
481,790
– – 0.03% 281
2025
Q3
$12.5M Hold
481,790
– – 0.02% 298
2025
Q2
$5.91M Hold
481,790
– – 0.01% 342
2025
Q1
$5.3M Buy
+481,790
New +$5.8M 0.01% 346

Other funds holding MAZE

Bessemer Group's MAZE Position: Q3 2026 in Review

Bessemer Group increased its Maze Therapeutics (MAZE) stake by 3% in Q3 2026, buying an estimated $401K and bringing the position to 496,253 shares worth $13.5M. The position accounts for 0.02% of the portfolio, ranked #347.

Bessemer Group first reported a position in MAZE in Q1 2025 and has held it in 7 quarters since. The position peaked at $20M in Q4 2025. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Bessemer Group held 496,253 shares of Maze Therapeutics worth $13.5M as of Q3 2026.
  • Bessemer Group bought 14,463 Maze Therapeutics shares in Q3 2026, an estimated $401K.
  • Maze Therapeutics made up 0.02% of Bessemer Group's portfolio in Q3 2026, its #347 holding.
  • Bessemer Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Bessemer Group's Maze Therapeutics position peaked at $20M in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Bessemer Group's 13F filing for Q3 2026, filed 9 Nov 2026.